Thermo Fisher Scientific Inc.

TMO Healthcare Diagnostics & Research

Thermo Fisher Scientific Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.6 billion, up 3.91% from fiscal 2024.

Revenue
+9.13%
EPS
+8.64%
Free cash flow
+15.0%
Total debt
+22.8%

Quarter to September 2026, against a year earlier

679.52 26.64 −3.77%
Market cap
$250.8B
P/E
35.8×
Fwd P/E
35.7×
Dividend yield
0.27%
F-score
5/9
Altman Z
3.84
Beneish M
−2.46
Dividend safety
88/100
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
P/E ratio
35.55 26.93 26.98 32.61

+8 more quarters

P/S ratio
5.27 4.01 4.05 4.90
P/FCF ratio
32.71 25.27 26.93 34.47
P/Operating CF
97.95 87.53 153.40 63.19
P/B ratio
4.56 3.53 3.52 4.09
EV/Sales
5.97 4.77 4.86 5.48
EV/EBITDA
24.43 19.94 20.52 23.20
EV/FCF
37.03 30.04 32.36 38.54
Current Ratio
1.81 1.55 1.53 1.89
Net Debt/EBITDA
10.70 12.09 14.16 8.63
Debt/Equity
0.71 0.74 0.77 0.67
Earnings Yield
2.81% 3.71% 3.71% 3.07%
Free Cash Flow Yield
3.06% 3.96% 3.71% 2.90%
Free Cash Flow per Share
5.71 4.53 2.22 8.01
Book value per Share
148.02 142.01 139.62 141.68
Free Cash Flow
2,114.00 1,679.00 825.00 3,019.00
EV/EBIT
33.39 27.14 27.83 31.52
Other line items

Show all line items

Columns are period end dates · fundamentals updated 3 Nov 2026